People

Stefan Lohmer
Co-founder, Chairman, Chief Executive Officer

Stefan is a co-founder, Chairman of the Board of Directors and Chief Executive Officer. Prior to founding Axxam, he was head of the assay development unit at the Bayer Research Centre in Milan and the Head of Genomics worldwide for Bayer AG. He was responsible for generating and managing Bayer's external genomic alliances with Millennium and Lion Bioscience. Stefan Lohmer joined Bayer in 1992. He holds a degree in Molecular Biology and Biochemistry from the University of Cologne and completed his PhD at the Max Planck Institute for Plant Breeding in Cologne.

Alessandro Sidoli
Co-founder, Chief Executive Officer

Alessandro Sidoli is the co-founder and Chief Executive Officer of Axxam as well as Managing Director of IMAX Discovery GmbH and a member of the Board of Directors of Xbrane Biopharma AB.
He has been President of Assobiotec/Federchimica, the Italian association for the development of the biotech industry, since May 2010, after having been Vice President since 2004. Since 2013 he has been a member of the Presidency Committee of Federchimica, in charge of new technological enterprises and from 2016 he is Chairman of Federchimica’s Research Development and Innovation Committee.
In 2015 he founded a business angels association focused on biotechnology (Italian Angels for Biotech), being is Vice President.
He started his career in 1982 as a Research Scientist at the Biotechnology Department of Farmitalia Carlo Erba in Milan, and later he was also a researcher at the Sir William Dunn School of Pathology at Oxford University (UK). From 1986 through 1989 he served as Head of the Biotechnology Department at the Istituto Sieroterapico Milanese (Milan). During the ‘90s he founded and served as Chief Executive Officer of Primm, one of the first Italian biotech companies, and was also Director of Technology Transfer at San Raffaele in Milan.
He is the author of more than 50 scientific publications and holds several national and international patents.
Born in Milan in 1959, Alessandro Sidoli received his degree in Biology from the University of Pavia where he conducted his studies as a member of the Ghislieri College

Luigi Gavazzeni
Chief Financial Officer, Board of Directors

Luigi has been Chief Financial Officer of Axxam since 2005 and a Board member since 2016. Prior to Axxam, he held Finance Director positions at BioXell SpA and Novuspharma SpA. He has successfully managed several strategic and corporate development projects for a number of companies in the biopharmaceutical industry. He has extensive experience in project management and a broad knowledge of finance, accounting and tax principles, regulations and financial control. Luigi received his Degree in Engineering from the Polytechnic in Milan.

Silvia Bottinelli
Director Human Resources

Silvia joined Axxam in 2008 to lead the Human Resources Department. She has over 15 years experience in the HR field, having worked with a number of Italian and multinational pharmaceutical companies, as well as in other industries. After starting her career with a headhunting company, she had her first in-company experience in the HR department of Siemens S.p.A, where she worked until 2001 as Recruiting Manager. From 2001 to 2005 she worked for Janssen-Cilag S.p.A, a pharmaceutical subsidiary of the Johnson & Johnson Group, as Recruiting and Development Manager. Before joining Axxam, Silvia worked as Human Resources Manager at Siena Biotech (2005–2008). Silvia holds a degree in Philosophy and Psychology from the University of Milan.

Lia Scarabottolo
Director Discovery Services

Lia has been Director of Discovery Services since 2007. She is responsible for Assay Development, High Throughput Screening, Compound Profiling, Hit Follow-up, Liability Platforms, Library and Data Management. She coordinates numerous collaborations with international companies and she is Work Package Leader for different grants supported by the Italian government and the European Community.
Before taking this role, she was Head of the Cell Biology unit at Axxam from 2001, and previously she was Head of Cardiovascular Research Unit in the Pharmacology Department at Bayer-Italy. She holds a degree in Pharmaceutical Chemistry and a Master in Experimental Pharmacology from the University of Milan.

Sabrina Corazza
Director Business Development

Member of the Axxam Team as of 2001, responsible for the BD activities of the Company since November 2009, Sabrina has been appointed Director, Business Development at Axxam in March 2015. Prior to that, she was head of the Enabling Technologies group at Axxam. Before joining Axxam in 2001, she was responsible for coordinating assay development in the CNS field at the Bayer Research Centre, based in Milano. Sabrina holds a degree in Biology from the University of Milano.

Giorgio Chirivì
Board of Directors

Giorgio has sat on Axxam’s board since the company's inception. He works for UBI Banca (formerly Centrobanca), one of the major Italian banking groups, engaged in mergers and acquisitions. Previously he served as the head of the corporate finance division for Arca BIM and was responsible for the mergers and acquisitions activities of the Credit Merchant Affairs Bank of the Credito Italiano Group.

Roberto Consonni
Board of Directors

Roberto has been a Board member since 2012. He is currently CEO of Zambon Company and also serves as a Board Member at Newron  Pharmaceuticals and Italia Assistenza. He spent his 40-year career in various business, working for both Italian and multinational companies.

Russell Thomas
Director, Discovery Research

Russell Thomas is Director of Discovery Research. Prior to joining Axxam in 2015, he was General Manager of Siena Biotech, having previously held the positions of Head of Medicinal Chemistry and then as Director of Portfolio Operations and Alliances.
Between September 2012 and November 2013 he was VP of Lead Discovery at Proteros in Munich Germany. He assisted in the startup of Rodin Therapeutics, co-founded by Proteros and Atlas Ventures. Between 1998 and 2004 he was Department Head at Evotec in Oxford, UK.
He worked at Glaxo, subsequently Glaxo Wellcome between 1991 and 1998 with positions of increasing responsibility in Medicinal Chemistry.
In his scientific career Russell Thomas has worked on a range of projects delivering clinical and preclinical candidates, including selisistat, currently in Phase II clinical trials for Huntington's disease.
Originally from Swansea, Wales, he graduated in chemistry from the University of Kent at Canterbury, followed by a Ph.D with Prof. Stan Roberts at Exeter University, UK.